3rd Apr 2014 07:04
LONDON (Alliance News) - Specialist healthcare company BTG PLC said Thursday that it expects revenue for year ended March 31 to be around the top end of its guidance range of GBP275 million to GBP285 million.
The company saw a strong performance in its Interventional Medicine Business, driven by the continued expansion of its embolisation and drug-eluting bead products, and new revenues coming in from its acquisition of live cancer treatment TheraSphere and EKOS Corporation in July 2013.
It also saw higher licensing revenue boosted by the increased use of Johnson & Johnson's prostate cancer treatment Zytiga.
Its Speciality Pharmaceuticals business saw lower growth during the year as a result of its maturing antidote portfolio, BTG said.
BTG has continued to accelerate Phase III trials of TheraSphere for potential use in advanced primary liver cancer and in metastatic colorectal cancer.
The newly acquired EKOS business is continuing launch activities following US approval of its Varithena product, for the treatment of varicose and incompetent veins. BTG said it was following a phased US market entry strategy to build long-term value for the product.
Shares in BTG were trading up 4.2% at 563.94 pence Thursday morning shortly after the market open.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
BTG